 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Fatty Liver among Persons in a Community in Northern Italy
18 January 2000 | Volume 132 Issue 2 | Page 112
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy." It is in the 18 January 1999 issue of Annals of Internal Medicine (volume 131, pages 112-117). The authors are S. Bellentani, G. Saccoccio, F. Masutti, L.S. Crocè, G. Brandi, F. Sasso, G. Cristanini, and C. Tiribelli.
What is the problem and what is known about it so far?
Positive blood tests for liver abnormalities occur fairly often and can be caused by many different liver diseases. Steatosis (fatty deposits in the liver) is often the only condition found in people with abnormal liver tests. Fatty liver is usually a benign condition that does not progress to liver damage, although it can lead to worry and unnecessary medical testing. Little is known, however, about just how common fatty liver really is; we also have little information on the risk factors, such as alcohol use and obesity, that might be associated with it.
Why did the researchers do this particular study?
The researchers wanted to determine how common fatty liver actually is in a general population. They also wanted to see whether persons with fatty liver are more likely to drink alcohol and be overweight than persons without this condition.
Who was studied?
As part of a larger study of liver disease in two Northern Italian communities, the researchers studied four groups of people: 1) 2,753 normal-weight persons who drank little or no alcohol, 2) 283 obese persons who drank little or no alcohol, 3) 168 normal-weight persons who were heavy alcohol drinkers, and 4) 95 persons who were both obese and heavy alcohol drinkers.
How was the study done?
The researchers did physical examinations and performed blood tests for liver abnormalities and ultrasound tests of the liver on all study participants. The ultrasound was the test that showed whether there was fat in the liver. The ultrasound in combination with the other tests let the researchers rule out other types of liver disease.
What did the researchers find?
Fatty liver was present in 16% of normal weight non-drinkers, 46% of heavy drinkers, 76% of obese non-drinkers, and 95% of obese heavy drinkers.
What were the limitations of the study?
This study included only people living in two communities in a single country. It is unclear whether the same results would occur in different geographic regions. Although the researchers made every effort to accurately measure how much alcohol study participants drank, they used the participants' own estimates, and participants may not have accurately estimated how much alcohol they consume.
What are the implications of the study?
Both being overweight and drinking alcohol are associated with fatty liver, but being overweight appears to be associated with a greater accumulation of fat in the liver than does drinking alcohol.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J L Newton, D E J Jones, E Henderson, L Kane, K Wilton, A D Burt, and C P Day Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance Gut, June 1, 2008; 57(6): 807 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fujimoto, K. Tsuneyama, M. Kainuma, N. Sekiya, H. Goto, Y. Takano, K. Terasawa, C. Selmi, M. E. Gershwin, and Y. Shimada Evidence-Based Efficacy of Kampo Formulas in a Model of Non Alcoholic Fatty Liver Experimental Biology and Medicine, March 1, 2008; 233(3): 328 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Rector, J. P. Thyfault, R. T. Morris, M. J. Laye, S. J. Borengasser, F. W. Booth, and J. A. Ibdah Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats Am J Physiol Gastrointest Liver Physiol, March 1, 2008; 294(3): G619 - G626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dongiovanni, L. Valenti, A. Ludovica Fracanzani, S. Gatti, G. Cairo, and S. Fargion Iron Depletion by Deferoxamine Up-Regulates Glucose Uptake and Insulin Signaling in Hepatoma Cells and in Rat Liver Am. J. Pathol., March 1, 2008; 172(3): 738 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Bruno, C. E. Dugan, J. A. Smyth, D. A. DiNatale, and S. I. Koo Green Tea Extract Protects Leptin-Deficient, Spontaneously Obese Mice from Hepatic Steatosis and Injury J. Nutr., February 1, 2008; 138(2): 323 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shibata, Y. Kihara, M. Taguchi, M. Tashiro, and M. Otsuki Nonalcoholic Fatty Liver Disease Is a Risk Factor for Type 2 Diabetes in Middle-Aged Japanese Men Diabetes Care, November 1, 2007; 30(11): 2940 - 2944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Savransky, S. Bevans, A. Nanayakkara, J. Li, P. L. Smith, M. S. Torbenson, and V. Y. Polotsky Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G871 - G877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kotronen, J. Westerbacka, R. Bergholm, K. H. Pietilainen, and H. Yki-Jarvinen Liver Fat in the Metabolic Syndrome J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3490 - 3497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Park, B. I. Kim, S. H. Kim, H. J. Kim, D. I. Park, Y. K. Cho, I. K. Sung, C. I. Sohn, H. Kim, D. K. Keum, et al. Body Fat Distribution and Insulin Resistance: Beyond Obesity in Nonalcoholic Fatty Liver Disease among Overweight Men J. Am. Coll. Nutr., August 1, 2007; 26(4): 321 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Saadeh Nonalcoholic Fatty Liver Disease and Obesity Nutr Clin Pract, February 1, 2007; 22(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Zhang, A. Hernandez-Ono, P. Siri, S. Weisberg, D. Conlon, M. J. Graham, R. M. Crooke, L.-S. Huang, and H. N. Ginsberg Aberrant Hepatic Expression of PPAR{gamma}2 Stimulates Hepatic Lipogenesis in a Mouse Model of Obesity, Insulin Resistance, Dyslipidemia, and Hepatic Steatosis J. Biol. Chem., December 8, 2006; 281(49): 37603 - 37615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Utzschneider and S. E. Kahn The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. P. J. Alwayn, C. Andersson, S. Lee, D. A. Arsenault, B. R. Bistrian, K. M. Gura, V. Nose, B. Zauscher, M. Moses, and M. Puder Inhibition of matrix metalloproteinases increases PPAR-{alpha} and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model Am J Physiol Gastrointest Liver Physiol, December 1, 2006; 291(6): G1011 - G1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. W. Hamer, D. A. Aguirre, G. Casola, J. E. Lavine, M. Woenckhaus, and C. B. Sirlin Fatty Liver: Imaging Patterns and Pitfalls RadioGraphics, November 1, 2006; 26(6): 1637 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Svegliati-Baroni, C. Candelaresi, S. Saccomanno, G. Ferretti, T. Bachetti, M. Marzioni, S. De Minicis, L. Nobili, R. Salzano, A. Omenetti, et al. A Model of Insulin Resistance and Nonalcoholic Steatohepatitis in Rats: Role of Peroxisome Proliferator-Activated Receptor-{alpha} and n-3 Polyunsaturated Fatty Acid Treatment on Liver Injury Am. J. Pathol., September 1, 2006; 169(3): 846 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Linden, L. William-Olsson, A. Ahnmark, K. Ekroos, C. Hallberg, H. P. Sjogren, B. Becker, L. Svensson, J. C. Clapham, J. Oscarsson, et al. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation FASEB J, March 1, 2006; 20(3): 434 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hamaguchi, T. Kojima, N. Takeda, T. Nakagawa, H. Taniguchi, K. Fujii, T. Omatsu, T. Nakajima, H. Sarui, M. Shimazaki, et al. The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease Ann Intern Med, November 15, 2005; 143(10): 722 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. W. Hamer, D. A. Aguirre, G. Casola, and C. B. Sirlin Imaging Features of Perivascular Fatty Infiltration of the Liver: Initial Observations Radiology, October 1, 2005; 237(1): 159 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Schadinger, N. L. R. Bucher, B. M. Schreiber, and S. R. Farmer PPAR{gamma}2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1195 - E1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bruno, P. Maisonneuve, P. Castellana, N. Rotmensz, S. Rossi, M. Maggioni, M. Persico, A. Colombo, F. Monasterolo, D. Casadei-Giunchi, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial BMJ, April 23, 2005; 330(7497): 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Adams, P. Angulo, and K. D. Lindor Nonalcoholic fatty liver disease Can. Med. Assoc. J., March 29, 2005; 172(7): 899 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Angelico, M. Del Ben, R. Conti, S. Francioso, K. Feole, S. Fiorello, M. G. Cavallo, B. Zalunardo, F. Lirussi, C. Alessandri, et al. Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1578 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Szczepaniak, P. Nurenberg, D. Leonard, J. D. Browning, J. S. Reingold, S. Grundy, H. H. Hobbs, and R. L. Dobbins Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E462 - E468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Cohen and J. M. Friedman Leptin and the Control of Metabolism: Role for Stearoyl-CoA Desaturase-1 (SCD-1) J. Nutr., September 1, 2004; 134(9): 2455S - 2463S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M Diehl Fatty liver, hypertension, and the metabolic syndrome Gut, July 1, 2004; 53(7): 923 - 924. [Full Text] [PDF]
|
|
|
|
|
|
G Donati, B Stagni, F Piscaglia, N Venturoli, A M Morselli-Labate, L Rasciti, and L Bolondi Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance Gut, July 1, 2004; 53(7): 1020 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Bray Medical Consequences of Obesity J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2583 - 2589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Dam-Larsen, M Franzmann, I B Andersen, P Christoffersen, L B Jensen, T I A Sorensen, U Becker, and F Bendtsen Long term prognosis of fatty liver: risk of chronic liver disease and death Gut, May 1, 2004; 53(5): 750 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.D.H. Malnick, M. Beergabel, and H. Knobler Non-alcoholic fatty liver: a common manifestation of a metabolic disorder QJM, October 1, 2003; 96(10): 699 - 709. [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Sollars, B. J. McEntee, J. B. Engiles, J. L. Rothstein, and A. M. Buchberg A novel transgenic line of mice exhibiting autosomal recessive male-specific lethality and non-alcoholic fatty liver disease Hum. Mol. Genet., October 15, 2002; 11(22): 2777 - 2786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Prati, E. Taioli, A. Zanella, E. D. Torre, S. Butelli, E. Del Vecchio, L. Vianello, F. Zanuso, F. Mozzi, S. Milani, et al. Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels Ann Intern Med, July 2, 2002; 137(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Kaplan Alanine Aminotransferase Levels: What's Normal? Ann Intern Med, July 2, 2002; 137(1): 49 - 51. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Angulo Nonalcoholic Fatty Liver Disease N. Engl. J. Med., April 18, 2002; 346(16): 1221 - 1231. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
